Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets

Resuscitation

Volumn 69, Issue 2, 2006, Pages 287-294

  Obaid, Laila ^a   Johnson, Scott T ^a   Bigam, David L ^a   Cheung, Po Yin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Haemodynamics; Newborn; Phosphodiesterase; Pulmonary hypertension; Sildenafil; Surfactant

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; SILDENAFIL; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DRUG EFFECT; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NEWBORN; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HYPERTENSION, PULMONARY; INTUBATION, INTRATRACHEAL; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SURFACE-ACTIVE AGENTS; SWINE; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 33646140101     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2005.08.017     Document Type: Article

References (34)

1. Ogawa Y., and Shimizu H. Current strategy for management of meconium aspiration syndrome. Acta Paediatr 41 (2000) 241-245
2. Geggel R.L., Murphy J.D., Langleben D., Crone R.K., Vacanti J.P., and Reid L.M. Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. J Pediatr 107 (1985) 457-464
3. Greenough A. Expanded use of surfactant replacement therapy. Eur J Pediatr 159 (2000) 635-640
4. Yapicioglu H., Yildizdas D., Bayram I., Sertdemir Y., and Yilmaz H.L. The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulm Pharmacol Ther 16 (2003) 327-333
5. Rais-Bahrami K., Rivera O., Seale W.R., and Short B.L. Effect of nitric oxide in meconium aspiration syndrome after treatment with surfactant. Crit Care Med 25 (1997) 1744-1747
6. Hamdan A.H., and Shaw N.J. Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf. Arch Dis Child 72 (1996) F176-F179
7. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term (Cochrane Review). In: The Cochrane Library, Issue 2; 2004.
8. Arnold W.P., Mittal C.K., Katsuki S., and Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74 (1997) 3203-3207
9. Atz A.M., Adatia I., and Wessel D.L. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 62 (1996) 1759-1764
10. Truog W.E., and Castor C.A. Neonatal nitric oxide use: predictors of response and financial implications. J Perinatal 23 (2003) 128-132
11. Sanchez L.S., de la Monte S.M., Filippov G., Jones R.C., Zapol W.M., and Bloch K.D. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43 (1998) 163-168
12. Wilkens H., Guth A., König J., Forestier N., Cremers B., Hennen B., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
13. Ichinose F., Erana-Garcia J., Hromi J., Raveh Y., Jones R., Krim L., et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29 (2001) 1000-1005
14. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J. Med 327 (1992) 70-75
15. Travadi N., and Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. J Pediatr Pulmonol 36 (2003) 529-535
16. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266 (1994) L536-L543
17. Atz A.M., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91 (1999) 307-310
18. Mychaskiw G., Sachdev V., and Heath B.J. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular assist device. J Clin Anesth 13 (2001) 218-220
19. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension Comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
20. Watanabe H., Ohashi K., Takeuchi K., Yamashita K., Yokoyama T., Tran Q.K., et al. Hayashi H. sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71 (2002) 398-402
21. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
22. Erickson S., Reyes J., Bohn D., and Adatia I. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am Coll Cardiol 39 Suppl (2002) 402 abstract
23. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
24. Shekerdemian L.S., Ravn H.B., and Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165 (2002) 1098-1102
25. Schulze-Neick I., and Redington A. Sildenafil, nitric oxide and acute lung injury: Pathophysiology beats pharmacotherapy?. Pediatr Res 55 (2004) 370-371
26. Hoffman G.M., and Nelin L.D. Changes in shunt and dead space in a tripartite lung model in infants and children during nitric oxide inhalation. Anesthesiology 83 (1995) A1192 abstract
27. Schulze-Neick I., Hartenstein P., Li J., Stiller B., Nagdyman N., Hubler M., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108 suppl II (2003) II167-II173
28. Shekerdemian L.S., Ravn H.B., and Penny D.J. Interaction between inhaled nitric oxide and IV sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 55 (2004) 413-418
29. Mehats C., Andersen C.B., Filopanti M., Jin S.L., and Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signalling. Trends Endocrinol Metab 13 (2002) 29-35
30. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108 (2001) 671-680
31. Bernardino de la Serna J., Perez-Gil J., Simonsen A.C., and Bagatolli L.A. Cholesterol rules: direct observation of the coexistence of two fluid phases in native pulmonary surfactant membranes at physiological temperatures. J Biol Chem 279 (2004) 40715-40722
32. Lewis J.F., Tabor B., Ikegami M., Jobe A.H., Joseph M., and Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled versus nebulized surfactant. J Appl Physiol 74 (1993) 1256-1264
33. Finer N.N., Tierney A., Etches P.C., Peliowski A., and Ainsworth W. Congenital diaphragmatic hernia: developing a protocolized approach. J Pediatr Surg 33 (1998) 1331-1337
34. Wiswell T.E., Knight G.R., Finer N.N., Donn S.M., Desai H., Walsh W.F., et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109 (2002) 1081-1087